arGEN X (0QW0) Price & Analysis

Compare

2 Followers

0QW0 Stock Chart & Stats

Day’s Range― - ―

52-Week Range€456.60 - €656.80

Previous CloseN/A

Volume2.00

Average Volume (3M)12.79K

Market Cap

€36.66B

Enterprise Value€27.53B

Total Cash (Recent Filing)€3.26B

Total Debt (Recent Filing)€37.70M

Price to Earnings (P/E)29.8

Beta0.50

Next Earnings

Oct 30, 2025

EPS Estimate

3.92

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)3.27

Shares Outstanding61,199,900

10 Day Avg. Volume15,377

30 Day Avg. Volume12,795

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€697.14

Price Target Upside19.68% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Financial PerformanceBetter than expected US volume growth is offsetting US price headwinds.

Market PotentialAutoimmune disorders like MG and CIDP still have unmet need despite availability of multiple approved therapies, offering market potential for argenx.

Product DevelopmentVyvgart is the most advanced FcRn antagonist in development and sales in its first 12 full quarters on the market significantly exceeded expectations.

Bears Say

Price TargetThe price target is decreasing by 9% due to peer group multiple contraction and euro strengthening against the US dollar.

Revenue ConcernsThere is a calculated 7% downside to the share price if Vyvgart only generates revenues in its two existing FDA approved indications and empasiprubart isn’t launched.

arGEN X News

Argenx price target raised to EUR 700 from EUR 680 at Barclays

Barclays raised the firm’s price target on Argenx (ARGX) to EUR 700 from EUR 680 and keeps an...

4d ago

ARGX

Argenx price target raised to EUR 730 from EUR 700 at JPMorgan

JPMorgan raised the firm’s price target on Argenx (ARGX) to EUR 730 from EUR 700 and keeps an...

4d ago

ARGX

Argenx price target raised to EUR 655 from EUR 550 at Deutsche Bank

Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on Argenx (ARGX) to EUR 655 from EUR...

4d ago

ARGX

Argenx price target raised to $1,070 from $1,060 at Guggenheim

Guggenheim raised the firm’s price target on Argenx (ARGX) to $1,070 from $1,060 and keeps a Buy rating...

7d ago

ARGX

Argenx price target raised to $796 from $715 at Scotiabank

Scotiabank raised the firm’s price target on Argenx (ARGX) to $796 from $715 and keeps an Outperform rating...

7d ago

ARGX

Argenx price target raised to $775 from $750 at Evercore ISI

Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Argenx (ARGX) to $775 from $750 and...

7d ago

ARGX

Argenx price target raised to $880 from $829 at BofA

BofA raised the firm’s price target on Argenx (ARGX) to $880 from $829 and keeps a Buy rating...

7d ago

ARGX

Argenx price target raised to $778 from $708 at Oppenheimer

Oppenheimer analyst Leland Gershell raised the firm’s price target on Argenx (ARGX) to $778 from $708 and keeps...

7d ago

ARGX

Argenx price target raised to $788 from $680 at Baird

Baird analyst Joel Beatty raised the firm’s price target on Argenx (ARGX) to $788 from $680 and keeps...

7d ago

ARGX

Argenx price target raised to $774 from $720 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Argenx (ARGX) to $774 from $720 and keeps a Buy...

7d ago

ARGX

Argenx Se: Strong Buy Rating Backed by Robust Financial Performance and Strategic Advancements

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ARGX stock, giving a Buy rating today....

7d ago

ARGX

Argenx Se’s Strong Market Position and Impressive Financial Performance Drive Buy Rating

Analyst Douglas Tsao of H.C. Wainwright maintained a Buy rating on Argenx Se, boosting the price target to...

7d ago

ARGX

Argenx’s Vyvgart Sales Surpass Expectations, Driving Buy Rating with Promising Pipeline and Market Expansion

Yaron Werber, an analyst from TD Cowen, maintained the Buy rating on Argenx Se. The associated price target...

8d ago

ARGX

Argenx SE’s Strong Q2 Performance and Positive Outlook Reinforce Buy Rating

Argenx Se, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Derek Archila from...

8d ago

ARGX

0QW0 FAQ

What was arGEN-X SE’s price range in the past 12 months?

arGEN-X SE lowest share price was €456.60 and its highest was €656.80 in the past 12 months.

What is arGEN-X SE’s market cap?

arGEN-X SE’s market cap is €36.66B.

When is arGEN-X SE’s upcoming earnings report date?

arGEN-X SE’s upcoming earnings report date is Oct 30, 2025 which is in 83 days.

How were arGEN-X SE’s earnings last quarter?

arGEN-X SE released its earnings results on Jul 31, 2025. The company reported €3.268 earnings per share for the quarter, beating the consensus estimate of €2.641 by €0.627.

Is arGEN-X SE overvalued?

According to Wall Street analysts arGEN-X SE’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does arGEN-X SE pay dividends?

arGEN-X SE does not currently pay dividends.

What is arGEN-X SE’s EPS estimate?

arGEN-X SE’s EPS estimate is 3.92.

How many shares outstanding does arGEN-X SE have?

arGEN-X SE has 61,199,900 shares outstanding.

What happened to arGEN-X SE’s price movement after its last earnings report?

arGEN-X SE reported an EPS of €3.268 in its last earnings report, beating expectations of €2.641. Following the earnings report the stock price went up 14.552%.

Which hedge fund is a major shareholder of arGEN-X SE?

Currently, no hedge funds are holding shares in GB:0QW0

Company Description

arGEN-X SE

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

arGEN X (0QW0) Earnings & Revenues

Historic Earnings Reports

0QW0 Stock 12 Month Forecast

Average Price Target

€697.14

▲(19.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"464":"€464","605":"€605","746":"€746","534.5":"€534.5","675.5":"€675.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":745,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€745.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":697.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€697.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":650,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€650.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[464,534.5,605,675.5,746],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,580.62,593.2646153846154,605.9092307692308,618.5538461538462,631.1984615384615,643.843076923077,656.4876923076923,669.1323076923077,681.7769230769231,694.4215384615385,707.0661538461538,719.7107692307693,732.3553846153847,{"y":745,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,580.62,589.5830769230769,598.5461538461539,607.5092307692307,616.4723076923077,625.4353846153846,634.3984615384616,643.3615384615384,652.3246153846154,661.2876923076923,670.2507692307693,679.2138461538461,688.1769230769231,{"y":697.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,580.62,585.9569230769231,591.2938461538462,596.6307692307693,601.9676923076923,607.3046153846154,612.6415384615384,617.9784615384615,623.3153846153846,628.6523076923077,633.9892307692307,639.3261538461538,644.6630769230769,{"y":650,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":472.85,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":465.63,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":487.45,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":546.94,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":588.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":598.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":642.27,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":594.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":545.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":564.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":503,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":474.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":580.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >